Check all days at bottom and search for Hedgehog and GDC-0449 for each day. There are many hedgehog presentations, but it is not possible to tell if GDC-0449 will be mentioned in them. I did find at least one Infinity IPI-926 mention. Also search cudc-101 on Monday, the poster presentation is #15.
I beg to differ. The very first study is being presented by Jean Yang, it is the Gorlin's syndrome study. In addition the overall theme of all of the hedgehog presentations just gives more hope and evidence that it may OR does work on the other cancers shown on your link. You are correct that most of them aren't being presented at the upcoming AACR specifically but the theory behind the hedgehog for those cancer types is being presented IMO. GLTA and we only have a few weeks to find out if AACR will give us any additional insight into our investment.
Saying that can't be good without looking into it for yourself may not be good for your investing. Here are the links that I found when I did a search on hedgehog. The first link is to the 45 results that come up at the upcoming conference. Whether it is directly linked to 0449 by specific mention of it or indirectly linked through the totally new way of treating cancer that could arise with hedgehog, it is still good for 0449 and Curis IMO.
45 results for hedgehog at upcoming conference:
Targeting the hedgehog pathway in meduloblastoma and basal cell carcinoma (my comment, presented by Frederick De Sauvage)Wednesday, Apr 06, 2011, 9:30 AM -10:00 AM
Translation of Basic Science into Successful Clinical Outcomes
An investigator-initiated, phase II randomized, double-blind, placebo-controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients (my comment, this is 0449)
Opening Plenary Session: The Future of Cancer Research: Challenges and Opportunities (my comment, notice Von Hoff and Jean Yang's presentations)
The Hedgehog Signaling Pathway: Biology and Therapeutics (my comment, this is a major symposium which includes presentations by Jean Yang)
Stromal desmoplasia is induced by a hypoxia and HIF-1α mediated increase in sonic hedgehog formation in pancreatic cancer (my comment, this includes presentations by Von Hoff who has done other 0449 testing for bcc, could we find out how it is doing in pancreatic setting?)
Evaluation of optimal dosing schedule on steady-state pharmacokinetics of orally administered hedgehog pathway inhibitor GDC-0449 in cancer patients
Here is the search result for Von Hoff who may provide updates for 0449 in pancreatic cancer. Not all of these relate to hedgehog. I don't know for certain if his involvement in hedgehog with pancreatic cancer is 0449 related but I do know he was one of the lead investigators in Scottsdale for the phase 1 bcc testing.
Based on the above results, I am very optimistic we could get a decent amount of information out of the conference. IMO hedgehog is clearly viewed as a potentially game changing treatment option which could mean additional cancer types for 0449 to treat. GLTA, the next couple of weeks will be interesting to say the least.